Advisory Committee Validates Kythera’s Endpoint Collaboration With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Working on the first drug therapy to reduce submental fat, or “double chin," Kythera worked with FDA on developing appropriate efficacy measures – and earned a unanimous recommendation for approval from an advisory panel.